OBJECTIVES To evaluate in vitro interactions between paromomycin sulphate and the antileishmanial drugs meglumine antimoniate, amphotericin B, miltefosine and azithromycin against intracellular Leishmania (Leishmania) infantum chagasi, Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis amastigotes in peritoneal mouse macrophages. METHODS First, drug susceptibility was a...

2-n-propylquinoline is presently a drug-candidate for the treatment of visceral leishmaniosis in pre-clinical development. As this compound is in an oily state, it needs to be formulated and the objectives of this study are: to prepare a formulation; to demonstrate that the new salted formulation did not alter the activity of the active ingredient; and finally, that this activity was quite good...

Sporotrichosis is the most frequent subcutaneous mycosis in the world and its increasing incidence has led to the search for new therapeutic options for its treatment. In this study, we demonstrated that three structural analogues of miltefosine (TCAN26, TC19, and TC70) showed inhibitory activity against Sporothrix schenckii sensu stricto and that TCAN26 was more active in vitro than miltefosin...

TO THE EDITOR—In their comprehensive cohort study, Rijal and colleagues have explored the occurrence of failure in miltefosine treatment in 120 visceral leishmaniasis (VL) patients in Nepal; they observed an initial cure rate of 95.8% with an alarming relapse rate of 10.8% and 20.0% at 6 and 12 months, respectively [1]. Similar studies in India have reported declines in the success rate of milt...

Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration. As part of research to identify better treatments for VL and cutaneous leishmaniasis (CL), alte...

© 2014 The Authors. doi: 10.2340/00015555-1582 Journal Compilation © 2014 Acta Dermato-Venereologica. ISSN 0001-5555 Post-kala-azar dermal leishmaniasis (PKDL) is a recalcitrant dermatosis following apparent cure from visceral leishmaniasis (VL). Patients with PKDL are considered the sole reservoir for the parasite during inter-epidemic periods of VL in India (1). Mono-drug therapy has been rec...

This review describes the pharmacokinetic properties of the systemically administered antileishmanial drugs pentavalent antimony, paromomycin, pentamidine, miltefosine and amphotericin B (AMB), including their absorption, distribution, metabolism and excretion and potential drug-drug interactions. This overview provides an understanding of their clinical pharmacokinetics, which could assist in ...

OBJECTIVE To facilitate the choice of the best visceral leishmaniasis (VL) treatment strategy for first-line health services in (VL)-endemic areas, we compared in a formal decision analysis the cost and the cost-effectiveness of the different available options. METHODS We selected four drug regimens for VL on the basis of frequency of use, feasibility and reported efficacy studies. The point ...